Sangamo Therapeutics, Inc. Forecast, price target & analysts
Sangamo Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Sangamo Therapeutics, Inc. Classifications & Recommendation
Sangamo Therapeutics, Inc. Price Target
| Target Price | $2.04 |
| Price | $0.15 |
| Potential |
1,303.99%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Sangamo Therapeutics, Inc. 2027 .
The average Sangamo Therapeutics, Inc. target price is $2.04.
This is
1,303.99%
register free of charge
$5.25
3,513.21%
register free of charge
$1.26
768.89%
register free of charge
|
|
| A rating was issued by 11 analysts: 8 Analysts recommend Sangamo Therapeutics, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sangamo Therapeutics, Inc. stock has an average upside potential 2027 of
1,303.99%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 39.55 | 68.95 |
| 31.57% | 74.34% | |
| EBITDA Margin | -263.06% | -63.09% |
| 63.42% | 76.02% | |
| Net Margin | -310.82% | -116.44% |
| 83.43% | 62.54% |
7 Analysts have issued a sales forecast Sangamo Therapeutics, Inc. 2026 . The average Sangamo Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Sangamo Therapeutics, Inc. EBITDA forecast 2026. The average Sangamo Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Sangamo Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Sangamo Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.44 | -0.19 |
| 10.20% | 56.82% | |
| P/E | negative | |
| EV/Sales | 0.44 |
7 Analysts have issued a Sangamo Therapeutics, Inc. forecast for earnings per share. The average Sangamo Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sangamo Therapeutics, Inc....
Current Sangamo Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 10 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 24 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | May 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 10 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 04 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 24 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 07 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Mar 18 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
